Our Partners

Our Partners

Our Partners

AbbVie

In 2012, Inventiva signed a multi-year drug discovery collaboration with AbbVie which was extended in 2017. Through this collaboration, Inventiva leverages upon its discovery expertise and technology platforms to develop drug candidates targeting the nuclear receptor ROR-y, a very promising approach for the treatment of several autoimmune diseases, in particular psoriasis in its moderate to severe form.

This collaboration entitles Inventiva to receive research fees, milestone payments and sales royalties.

Boehringer Ingelheim

In 2016, Inventiva signed a multi-year drug discovery collaboration with Boehringer Ingelheim to jointly validate a new therapeutic target for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases. In 2017, Boehringer Ingelheim exercised an option to jointly discover novel therapeutic molecules modulating this now validated new target.

This collaboration entitles Inventiva to receive research fees, milestone payments and sales royalties.